Welcome to our dedicated page for Pharmala Biotech news (Ticker: MDXXF), a resource for investors and traders seeking the latest updates and insights on Pharmala Biotech stock.
PharmAla Biotech Holdings Inc. (OTCQB: MDXXF) is a biotechnology company in the healthcare sector that focuses on the research, development, and manufacturing of MDXX class molecules, including MDMA. Its news flow centers on clinical-grade MDMA supply agreements, progress in its ALA-002 development program, and updates on its role in MDMA-assisted therapy research.
Company announcements frequently highlight contracts to supply LaNeo MDMA for investigator-sponsored and other clinical trials at leading institutions. Recent releases describe shipments or supply agreements involving the University of Washington, Yale University, Johns Hopkins University, Mt. Sinai Health System, Østfold Hospital Trust in Norway, and the STRONG STAR Consortium led by UT Health San Antonio and Emory University. These updates often explain how LaNeo MDMA will be used in studies of conditions such as PTSD and personality disorders.
PharmAla’s news also covers developments in its pipeline, particularly ALA-002, a patented, novel, non-racemic MDMA formulation. The company has reported the issuance of a US patent for ALA-002 and has announced manufacturing arrangements for ALA-002 drug substance through its subsidiary PharmAla Biotech Australia and a UK-based CDMO.
Operational and regulatory milestones are another recurring theme, including new distribution and logistics partnerships, the launch of a clinical trial tool that provides researchers with access to CMC data and the Investigator’s Brochure, and corporate governance items such as option grants and advisory agreements. Investors and researchers following MDXX class drug development, MDMA-assisted therapy, and clinical trial supply can use this news page to review PharmAla’s disclosed contracts, research collaborations, and corporate updates over time.
Summary not available.